Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Current Leases (2019 - 2025)

C4 Therapeutics (CCCC) has 7 years of Current Leases data on record, last reported at $6.4 million in Q4 2025.

  • For Q4 2025, Current Leases rose 10.27% year-over-year to $6.4 million; the TTM value through Dec 2025 reached $6.4 million, up 10.27%, while the annual FY2025 figure was $6.4 million, 10.27% up from the prior year.
  • Current Leases reached $6.4 million in Q4 2025 per CCCC's latest filing, up from $6.2 million in the prior quarter.
  • Across five years, Current Leases topped out at $6.4 million in Q4 2025 and bottomed at $1.1 million in Q1 2021.
  • Average Current Leases over 5 years is $4.2 million, with a median of $5.0 million recorded in 2023.
  • Peak YoY movement for Current Leases: soared 288.87% in 2022, then grew 10.27% in 2025.
  • A 5-year view of Current Leases shows it stood at $1.3 million in 2021, then surged by 252.32% to $4.7 million in 2022, then increased by 11.04% to $5.2 million in 2023, then increased by 10.63% to $5.8 million in 2024, then grew by 10.27% to $6.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $6.4 million in Q4 2025, $6.2 million in Q3 2025, and $6.1 million in Q2 2025.